Skip to main content

Table 2 Outcome Ascertainment for INSIGHT

From: The rationale and design of Insight into Nephrotic Syndrome: Investigating Genes, Health and Therapeutics (INSIGHT): a prospective cohort study of childhood nephrotic syndrome

  Follow up time since initial onset (months)
  4 8 12 24 36 48 60
Remission: Urine protein/creatinine < 0.2 or Albustik negative or trace for 3 consecutive days x x x x x x x
Relapse: After remission, an increase in the first morning urine protein/creatinine ≥2 for 3 of 5 consecutive days x x x x x x x
Frequently relapsing NS: 4 or more relapses within 1 year OR 2 or more relapses within 6 months    x x x x x
Steroid dependant NS: Relapse during steroid taper or within 14 days of steroid discontinuation x x x x x x x
Steroid resistant: Inability to induce remission within 28 days of steroid therapy x x x x x   
Urine protein/creatinine: Abnormal if > 250 mg/mmol x x x x x x x
Urine albumin/creatinine: Abnormal if > 30 mg/mol x x x x x x x
Creatinine based eGFR: eGFR by modified Schwartz (ml/min/1.73 m2) = k x height/serum creatinine x x x x x x x
CKD/ESRD: eGFR < 60 ml/min/1.73 m2 (or dialysis)     Anytime